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IBD in Asia remain low compared with those in Western 
countries, but a rising trend has been recognized in recent 
years, providing strong evidence in support of the effect of 
the environment.4-7 The characteristics of Western and Asian 
patients with IBD differ in epidemiology, phenotype, clinical 
course, and genetic susceptibility.4,8-10 Korea has a relatively 
small land area and an ethnically homogeneous popula-
tion. Since the 1960s, when the first IBD cases in Korea were 
reported, the incidence and prevalence of IBD in Korea has 
been lower than that in Western countries but have demon-
strated rapidly increasing trends. Several distinct character-
istics of patients with IBD in Korea have been reported, such 
as thiopurine-induced leukopenia and the risk of opportu-
nistic tuberculosis (TB) infection in patients administered 
tumor necrosis factor-α (TNF-α) inhibitor.11-13 These distinct 
characteristics can provide important clues about etiology 
and pathophysiology, and comprehensive population-based 
INTRODUCTION
Inflammatory bowel disease (IBD), CD, and UC are 
chronic relapsing inflammatory disorders of the intestine 
with unknown causes. IBD develops upon the interaction 
between genetic predisposition leading to immunological 
abnormalities, environment, and microbiome. None of these 
factors alone are sufficient to induce disease development.1
The occurrence of IBD is increasing in North America, 
Europe, and worldwide.2,3 The incidence and prevalence of 
© Copyright 2015. Korean Association for the Study of Intestinal Diseases. All rights reserved.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
ISSN 1598-9100(Print) • ISSN 2288-1956(Online)
http://dx.doi.org/10.5217/ir.2015.13.3.213
Intest Res 2015;13(3):213-218
SPECIAL REVIEW: IBD and Epidemiology in Asia
Inflammatory Bowel Disease Cohort Studies in Korea: 
Present and Future
Jung Won Lee1, Jong Pil Im1, Jae Hee Cheon2, You Sun Kim3, Joo Sung Kim1, Dong Soo Han4
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine1, Department of Internal Medicine 
and Institute of Gastroenterology, Yonsei University College of Medicine2, Department of Internal Medicine, Inje University College of Medicine3, 
Seoul, Department of Internal Medicine, Hanyang University College of Medicine4, Guri, Korea
Inflammatory bowel disease (IBD) is defined as a chronic and relapsing inflammatory disorder of the intestine. Intestinal in-
flammation in IBD has been proposed to be attributable to the interplay between microbial, genetic, environmental, and im-
munological factors. The incidence and prevalence rates of IBD are rapidly increasing apparently in other parts of the world, 
with dramatic increases especially in East Asia. Generally, cohort studies are useful for estimating the incidence, prevalence, 
natural course, prognosis, and risk factors of diseases. In particular, cohort studies performed in Western countries have well 
described the prevalence, risk factors, and natural course of IBD and investigated its genetic pathophysiology. However, the out-
comes of IBD cohort studies performed in Korea are not as persuasive as those of Western studies because of the relatively low 
prevalence of IBD and short follow-up periods of the cohorts in Korea. Despite this critical limitation, members of the Korean 
Association for the Study of Intestinal Diseases have demonstrated outstanding results. Some unique features of IBD patients 
in Korea are well demonstrated, such as thiopurine-induced leukopenia or risks of opportunistic tuberculosis infection in pa-
tients receiving tumor necrosis factor-α inhibitors. In this review, the present authors summarized the key points of the results 
of the cohort studies performed in Korea and explored future perspectives. (Intest Res 2015;13:213-218)
Key Words: Inflammatory bowel diseases; Cohort studies; Korea
Received April 23, 2015. Revised April 26, 2015. Accepted April 30, 2015.
Correspondence to Jong Pil Im, Department of Internal Medicine and 
Liver Research Institute, Seoul National University Hospital, 101 Daehak-ro, 
Jongno-gu, Seoul 110-744, Korea.  Tel: +82-2-2072-0638, Fax: +82-2-762-
9662, E-mail: jpim0911@snu.ac.kr
Financial support: This work was supported by the research program 
funded by the Korea Centers for Disease Control and Prevention [2013-
E63004-01].  Conflict of interest: None.
Jung Won Lee, et al. • IBD Cohort Study in Korea
214 www.irjournal.org
studies are required to clarify these differences.6  
A cohort study is generally useful for estimating the inci-
dence, prevalence, disease course, prognosis, and other clini-
cally distinct features. Cohort studies conducted in Western 
Europe and America have described the IBD clinical course 
and identified its pathophysiology. Some unique features 
of patients with IBD in Korea have been well demonstrated 
by cohort studies in Korea, especially by members of the 
Korean Association for the Study of Intestinal Diseases (KA-
SID). However, most of the currently available data came 
from single-center and a few multi-center studies those were 
primarily retrospective in design.6 Potential problems with 
the retrospective cohort approach include selection and 
misclassification bias. Moreover, there have been no well-
designed prospective cohort studies in Korea. From this 
background, here we prepare the key findings of cohort stud-
ies of patients with IBD in Korea to date and explore future 
potential IBD cohort studies in Korea.
PAST AND PRESENT
The first systematic population-based cohort study was 
performed in the Songpa-Kangdong district of Seoul in 
1986.14 According to a recent update on the descriptive 
epidemiology of the Songpa-Kangdong district, the mean 
annual incidences of CD and UC increased significantly 
from 0.05 and 0.34 per 100,000 inhabitants, respectively, in 
1986−1990 to 1.34 and 3.08 per 100,000 inhabitants, respec-
tively, in 2001−2005. During this 20-year period, the ratio 
of the incidences of UC to CD was decreasing from 6.8 in 
1986−1990 to 2.3 in 2001−2005, indicating that CD demon-
strated a trend of a more accelerated incidence compared 
than UC in Korea.15 The clinical features of UC at diagnosis 
are reportedly similar in Koreans and Westerners. For exam-
ple, there are no differences in disease extent and severity at 
diagnosis or in the male-to-female ratio of patients with UC 
between Korea and Western countries. The cumulative risk 
of proximal extension in patients with proctitis or left-sided 
colitis was 33.0% after 5 years and 44.5% after 10 years. The 
cumulative probability of colectomy was 2.0% after 1 year, 
2.8% after 3 years, and 3.3% after 5−15 years. The cumula-
tive survival rates after 1, 5, and 10 years were 100%, 99.4%, 
and 97.4%, respectively. Korean patients with UC look like to 
have a milder course that results in a reduced risk of colec-
tomy compared to the Western population.16 Approximately 
1.1% of patients with UC are diagnosed with any UC-related 
symptoms. Most of these asymptomatic UC patients be-
come symptomatic during follow-up but appeared to have 
better prognosis than symptomatic UC patients.17
A male predominance in the prevalence of CD was ob-
served in the Korean population, a finding similar to those 
reported in recent studies from China and Japan,18 while the 
incidence of CD in females is predominant or equal to that 
in males in Western countries.4,19 Patients with CD may have 
a similar clinical course to Westerners, especially regarding 
the intestinal resection rate. The surgery rate has decreased 
as time passes, which was related to the early administration 
of azathioprine/6-mercaptopurine (AZA/6-MP).20 How-
ever, Korean patients with CD are more likely than Western 
patients to have jejunal involvement. Jejunal involvement 
is a factor of poor prognosis in both Korean and Western 
patients with CD.21 Moreover, perianal fistulas seemed more 
common in Korean patients than in Westerners.22
The early administration of biological agents showed 
improved outcomes of IBD; consequently, increasing num-
bers of patients with IBD are expected to receive TNF-α 
inhibitor therapy.23,24 One of the most feared side effects is 
an increased risk of opportunistic TB infection, especially in 
an IBD population from a TB endemic area.25,26 The KASID 
conductive retrospective cohort study aimed to define the 
risk of TB in a large cohort of 873 IBD patients using TNF-α 
inhibitors compared with the matched general population 
and identify the detailed clinical characteristics of and risk 
factors for newly developed TB in patients with IBD. A total 
of 25 newly developed TB cases—21 (84%) pulmonary and 
4 (16%) extra-pulmonary infections—were identified in the 
cohort. The adjusted standardized incidence ratio (SIR) of 
TB was 41.7 (95% CI, 25.3−58.0), but the outcomes of anti-TB 
treatment were primarily favorable.27
The risks and characteristics of colorectal cancer (CRC) in 
IBD were also assessed.28 The population-based nationwide 
study was conducted to investigate the incidence of CRC in 
patients with UC. The KASID reviewed 7,061 cases of UC 
that occurred between 1970 and 2005 and found a total of 
26 cases of CRC. They reported that the cumulative risk of 
UC-associated CRC was 0.7% for patients that had UC for 
10 years, 7.9% for 20 years, and 33.2% for 30 years. The mean 
duration of UC before the development of CRC was 11.5 
years.29 Another study from a well-defined hospital-based 
cohort was recently published. A total of 5,212 patients with 
IBD (2,414 with CD and 2,798 with UC) were followed up 
for 39,951 person-years, thus a mean follow-up duration of 
7.7 years. Thirty patients (12 with CD and 18 with UC) devel-
oped CRC. The SIR of CRC was 6.0 (95% CI, 3.10−10.48) for 
CD and 1.68 (95% CI, 1.00−2.66) for UC. The SIR of CRC in 
Korean patients with UC may be similar to that in Western 
patients with UC. In contrast to Western patients with CD, 
the most common site of CRC in Korean patients with CD 
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is the low rectum, probably in accordance with the higher 
prevalence of perianal fistulas in Korean patients with CD.30
Thiopurine-associated leukopenia could be a life-threat-
ening side effect of AZA/6-MP in IBD treatment, and Korean 
patients seem to experience myelotoxicity more frequently 
(31−56%) than patients of European descent.11 Although 
thiopurine methyltransferase (TPMT) genotypes and activ-
ity could not clarify the thiopurine-induced leukopenia com-
pletely, it was proposed that TPMT genotypes and activity 
measurements before AZA/6-MP administration might help 
to predict the development of leukopenia.31 Recently, using 
the sample from cohort of 978 CD patients treated with thio-
purine, a nonsynonymous single nucleotide protein (SNP) 
in NUDT15 (encoding p.Arg139Cys) was strongly associated 
with thiopurine-induced early leukopenia in both Korean 
and United States patients with IBD.32 These findings ex-
plain, in part, the higher prevalence of thiopurine-associated 
leukopenia in Asians despite the lower prevalence of TPMT 
mutations. These results highlight genetic or biomarker stud-
ies require blood or tissue specimens from a large number of 
patients with accurate, matched clinical data.
In addition to leukopenia, growing evidence supports the 
existence of a correlation between thiopurine treatment and 
the increased risk of developing lymphoma. Patients with 
lymphoma and IBD from three tertiary referral centers in 
Korea were analyzed. Seven cases of lymphoma (0.1%) were 
identified in 6,585 patients with IBD. Three patients had UC 
and 4 had CD. Non-Hodgkin lymphoma was diagnosed in 5 
patients (71.4%) and Hodgkin disease in 2 patients (28.6%). 
The SIR of lymphoma was 2.03 (95% CI, 0.81−4.18) in the en-
tire IBD patients and the SIR of lymphoma in patients with 
CD was 9.31 (95% CI, 1.13−33.62). The SIR of lymphoma in 
patients who were exposed to thiopurines was 5.93 (95% 
CI, 1.61−15.18). The risk of lymphoma in patients with CD 
seems to be increased and thiopurine may be related with 
the risk of lymphoma in Korean patients with IBD.33
Since genome-wide association studies (GWAS) have 
been introduced in an effort to identify the etiological fac-
tors of IBD,34 many genetic polymorphisms related to an 
increased risk of IBD have been identified based on an es-
tablished IBD cohort.35 TNFSF15  is a proven susceptibility 
gene for CD. The associations among five TNFSF15  SNPs 
and various clinical parameters were investigated using a 
total of 906 patients with CD and TNFSF15  genotype data 
with clinical information. In Korean patients with CD, non-
risk allele homozygotes of the TNFSF15  SNPs rs6478108 
and rs4574921 are independent genetic predictive factors 
for the development of strictures/non-perianal penetrating 
complications and perianal fistula.36 GWAS was performed 
in the Korean population comprising a total of 2,311 patients 
with CD, 2,442 controls derived from the IBD Clinic of Asan 
Medical Center, and 792 from the Korea Research Network 
for Crohn’s Disease. In this study, three new susceptibility 
loci demonstrated genome-wide significance: rs6856616 
at 4p14 (OR, 1.43; combined P =3.60 ×10-14), rs11195128 at 
10q25 (OR, 1.42; combined P =1.55 ×10-10), and rs11235667 
at 11q13 (OR, 1.46; combined P=7.15 ×10-9).37
FUTURE
Attempts to comprehensively understand the epidemio-
logic, clinical, and genetic characteristics of Korean patients 
with CD first started in 2008. Won Ho Kim, President of the 
KASID at that time, earned a national grant entitled the 
“Research Network for Crohn’s Disease.” During the study 
period, active translational research was performed using 
clinical data from about 2,000 blood samples of 1,316 Ko-
rean patients with CD. The study team also established the 
Korean diagnostic and therapeutic guidelines for CD with 
the help of the IBD Study Group of KASID that published the 
diagnostic guidelines for intestinal TB, a disease often mis-
diagnosed as CD.6 After the Research Network for Crohn’s 
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Fig. 1. The progress of three studies of the 
Crohn’s Disease Clinical Network and Co-
hort (CONNECT) study. KASID, Korean Asso-
ciation for the Study of Intestinal Diseases.6
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Disease study, a subsequent study named “Establishment of 
Crohn’s disease in Korea and characterization of clinical fea-
tures with long-term follow-up” was conducted from January 
2012 to December 2013 led by Dong Soo Han. Retrospective 
clinical data before 2009 and prospective data for patients 
enrolled during and after 2009 were collected using a novel 
web-based well-recorded, high-quality electronic case report 
form system. Data for 1,388 retrospective patients and 890 
prospective patients including 635 blood specimens were 
collected and analyzed.
In 2012, Korea Centers for Disease Control and Preven-
tion solicited grant applications for a 6-month demonstra-
tion project aimed at establishing a CD network. The KASID 
obtained this grant, and in 2012, a 3-year national grant from 
the Korea Centers for Disease Control and Prevention. The 
new study funded by these grants was named “Establishment 
and Management of Crohn’s Disease Research Network”. 
Recently, the latter two studies discussed above were inte-
grated into a single study referred to as the “Crohn’s Disease 
Clinical Network and Cohort” (CONNECT) study led by Joo 
Sung Kim (Fig. 1).
A total of 34 institutions are now participating in this study, 
and more than 2,000 blood specimens have been collected 
to date. More than 20 studies using a retrospective cohort of 
1,382 patients are underway and some results were present-
ed at the KASID, Asian Organization for Crohn’s and Colitis, 
and European Crohn’s and Colitis Organization meetings. 
The baseline characteristics of patients with a follow-up 
period ≥6 months are shown in Table 1. Men comprised 
69.5% and the median age at diagnosis was 24 years. A total 
of 2.1% of patients had a family history of IBD. According to 
the Montreal classification, ileocolonic location (L3) was the 
most common, followed by the ileal (L1) and colonic (L3) 
locations. In 1,016 (79.5%) patients, the disease behavior at 
diagnosis was inflammatory. Of the patients, 560 (43.8%) 
and 144 (11.3%) had perianal disease and stenosis at diag-
nosis, respectively.
The first result led by Dong Il Park was recently published 
about long-term clinical outcomes of Korean patients with 
CD in urban versus rural environments. Although numerous 
studies have reported a positive correlation between urban 
environment and CD development, no differences were 
found in terms of disease presentation and natural history 
between Korean urban and rural populations except for a 
higher rate of surgery in the urban population of patients 
recently diagnosed with CD.38 You Sun Kim et al. conducted 
the study to determine the incidence of free perforation, the 
clinical characteristics of patients with CD and free perfora-
tion, and the risk factors associated with free perforation in 
patients with CD in Korea. Eighty-eight (6.4%) of the 1,382 
patients had free perforation, and multivariate analysis re-
vealed that free perforation was significantly associated with 
age ≥30 years at diagnosis (OR, 2.082; P =0.002) and bowel 
stricture (OR, 1.982; P =0.004).39 These retrospective data-
based studies will be the background for future prospectively 
enrolled cohort studies to investigate the clinical course and 
pathophysiology of Korean patients with CD. As of March 
2015, 1,302 patients diagnosed with CD after 2009 with 850 
Table 1. Baseline Characteristics of Retrospective Cohort Study With 
Follow-Up Period of 6 Months or More
Characteristics CD cohort (n=1,278 )
Baseline characteristics at diagnosis
Demographic data
   Age, yr, median (range) 24.0 (7-87)
   Male gender 888 (69.5)
   BMI, kg/m2, median (range) 19.0 (12-41)
Family history of IBD 27 (2.1)
Presence of granuloma 412 (32.2)
Location (involvement)
   Jejunum 200 (15.6)
   Ileum 1,003 (78.5)
   Colorectal 941 (73.6)
   Upper GI tract 91 (7.1)
Montreal classification
   Age at diagnosis
   <16 yr (A1) 121 (9.5)
   17–40 yr (A2) 972 (76.1)
   >40 yr (A3) 178 (13.9)
Location
   Ileal (L1) 291 (22.8)
   Colonic (L2) 229 (17.9)
   Ileocolonic (L3) 712 (55.7)
   Isolated upper disease (L4) 15 (1.2)
Behavior
   Inflammatory (B1) 1,016 (79.5)
   Stricturing (B2) 120 (9.4)
   Penetrating (B3) 143 (11.2)
Perianal lesions 560 (43.8)
Stenosis 144 (11.3)
Values are presented as n (%).
GI, gastrointestinal.
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serum samples are registered and prospectively followed-up 
in the national CONNECT study.6 We regularly audit the data 
and send a newsletter to the investigators to remind them of 
the importance of accurate and complete data acquisition. 
Investigators from the CONNECT study anticipate that the 
typical clinical characteristics and genetic causes of CD in 
Korean patients will be elucidated.
Despite the established nationwide CD cohort study in 
Korea, there has been little nationwide systematic data on 
epidemiology, clinical characteristics, and genetics of Korean 
patients with UC. There is an urgent need for the nationwide 
collection of well-defined clinical characteristics of Korean 
patients with UC and their blood samples. Hyo-Jong Kim, as 
coordinating investigator, and the other associated KASID 
members initiated the first nationwide “Cohort study of new-
ly diagnosed moderate to severe ulcerative colitis in Korea” 
(MOSAIK). This is a multicenter, nationwide, prospective, 
5-year follow-up longitudinal, disease-oriented, and hospital-
based cohort study. Patients newly diagnosed with moder-
ate to severe UC in tertiary referral centers are to be included 
in this study. The aim of the MOSAIK study is to establish a 
UC research cohort for the investigation of epidemiology, 
clinical characteristics, and genetics of Korean patients with 
UC by collecting well-defined clinical and follow-up charac-
teristics of Korean patients with UC and their blood samples 
with a goal of recruiting 400 patients. As of April 2015, >100 
patients diagnosed with UC from 27 hospitals are registered. 
The MOSAIK cohort will be closed when the last patient 
completes the last scheduled 5-year follow-up visit. The 
clinical characteristics and genetic causes of Korean patients 
with UC could be elucidated through the MOSAIK cohort 
study results.
CONCLUSIONS
It is widely accepted that a cohort study with a prospec-
tive design would be a very appropriate for epidemiologic 
study. No well-designed nationwide cohort study of IBD has 
been published in Korea to date. However, recent long-term 
follow-up results from the IBD cohort study might help clini-
cians and researchers to make more clear decisions. These 
findings, together with the distinct demographic and pheno-
typic characteristics of Korean patients with IBD, may pro-
vide clues to the etiology of these diseases as well as useful 
information for health care policy. Even though the initiation 
of IBD cohort studies in Korea was quite behind compared 
to Western studies, there are some clinical and genotypic 
characteristics unique to Korean patients with IBD like thio-
purine-induced side effects and opportunistic TB infections. 
These unique features could provide important implications 
about the etiology and pathophysiology of IBD through a 
comprehensive population-based study. Moreover, studies 
regarding biosamples might strengthen the impact of the co-
hort study.
In an IBD cohort study, the typical clinical characteristics 
and genetic causes of Korean patients with IBD could be 
elucidated, which will be a basis for further research into the 
clinical and genetic characteristics of IBD in Korea. Further 
diagnosis and treatment guidelines and new therapeutic 
agents for Korean patients with IBD will be developed based 
on these cohort findings.
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